(IN BRIEF) Novartis has reported final Phase III ALIGN study results showing that Vanrafia (atrasentan) slowed kidney function decline in adults with IgA nephropathy compared with placebo. At Week 136, the therapy demonstrated a 2.39 ml/min/1.73m² difference in eGFR change … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged accelerated approval United States China, ALIGN study, atrasentan, EGFR, endothelin A receptor antagonist, Fabhalta, Final ALIGN Data Support Vanrafia as Potential Foundational Therapy to Slow Kidney Function Decline in IgAN, IgA nephropathy, IgAN, iptacopan, kidney disease, Novartis, Novartis Advances IgA Nephropathy Portfolio with Positive Long-Term Phase III Results for Vanrafia, phase III clinical trial, proteinuria, RAS inhibitors, renal function decline, Ruchira Glaser, SGLT2 inhibitors, Vanrafia, zigakibart
(IN BRIEF) Roche announced that its Phase III INShore trial evaluating Gazyva/Gazyvaro (obinutuzumab) in children and young adults with idiopathic nephrotic syndrome met its primary endpoint, showing superior sustained remission rates at one year compared to mycophenolate mofetil (MMF). The … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged B cell targeting, Basel, Chronic kidney disease, corticosteroids, EMA, FDA, Gazyva, Gazyva/Gazyvaro Demonstrates Superior Sustained Remission in Children and Young Adults With Idiopathic Nephrotic Syndrome, Gazyvaro, idiopathic nephrotic syndrome, immune-mediated kidney diseases, INS, INShore study, Levi Garraway, lupus nephritis, NOBILITY study, obinutuzumab, pediatric nephrology, phase III clinical trial, proteinuria, REGENCY study, renal disease, Roche, Roche Announces Positive Phase III INShore Results for Gazyva/Gazyvaro in Children and Young Adults With Idiopathic Nephrotic Syndrome, sustained remission, targeted therapy
(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A receptor antagonist, for the treatment of IgA nephropathy (IgAN). The study demonstrated that atrasentan significantly reduced proteinuria (excess protein in … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?